Goulooze SC, Snelder N, Seelmann A, Horvat-Broecker A, Brinker M, Joseph A, Garmann D, Lippert J, Eissing T. Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria. Clin Pharmacokinet. 2021. [Link to publication]
Willmann S., Coboeken K., Zhang Y, Mayer H., Ince I, Mesic E., Thelen K., Kubitza D., Lensing A.W.A., Yang H., Zhu P., Mück W., Drenth H., Lippert J. Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions. CPT Pharmacometrics Syst Pharmacol. 2021 Jul 22. doi: 10.1002/psp4.12688 . [Link to publication]
Snelder N., Heinig R., Drenth H.J., Joseph A., Kolkhof P., Lippert J., Garmann D., Ploeger B., Eissing T. Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease. Clin Pharmacokinet. 359-370 :2020. [Link to publication]
Hoefman S., Snelder N., van Noort M., Garcia-Hernandez A., Onkels H., Larsson T.E., Bergmann K.R. Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease. J Pharmacokinet Pharmacodyn. 2020 [Link to publication]
Snelder N., Hoefman S., Garcia-Hernandez A., Onkels H., Larsson T.E., Bergmann K.R. Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model. J Pharmacokinet Pharmacodyn. 2020 [Link to publication]
Snelder N., Ploeger B.A., Luttringer O., Rigel D.F., Webb R.L., Feldman D., Fu F., Beil M., Jin L., Stanski D.R. and Danhof M., Characterization and prediction of cardiovascular effects of fingolimod and siponimod using a systems pharmacology modelling approach, J Pharmacol Exp Ther, 1(116): 236208, 2016. [Link to publication]
Bosch R., K.Bergmann, Baverel P., Fairman D., Vis P. and Agoram B., A mechanism-based model is able to simultaneously explain the effect of rhLCAT and HDL mimetics on biomarkers of reverse cholesterol transport. PAGE.(2015) [Link to publication]
Snelder N., Ploeger B., Luttringer O., Rigel D., Webb R., Feldman D., Fu F., Beil M., Jin L., stanski D. and Danhof M., Characterization and prediction of cardiovascular effects of S1P receptor agonists; a Systems pharmacology modeling approach. Noordwijkerhout.(2014)
Snelder N., Ploeger B., Luttringer O., Rigel D., Webb R., Feldman D., Fu F., Beil M., Jin L., stanski D. and Danhof M., Characterization and prediction of cardiovascular effects of S1P receptor agonists; a Systems pharmacology modeling approach. Noordwijkerhout.(2014)
Bergmann K., Fairman D. and Vis P., Mechanism based PK/PD model for the effect of rhLCAT and apoA-I preparations on reverse cholesterol transport. Noordwijkerhout.(2014)
- « Previous
- 1
- 2
- 3
- 4
- Next »